• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整体回顾与荟萃分析:SYNTAX 残余评分对急性冠脉综合征患者预后的独立影响。

Holistic review and meta-analysis of independent impact of the residual SYNTAX score on prognosis in patients with acute coronary syndrome.

机构信息

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

出版信息

Scand Cardiovasc J. 2022 Dec;56(1):187-197. doi: 10.1080/14017431.2022.2095434.

DOI:10.1080/14017431.2022.2095434
PMID:35788166
Abstract

. The appropriate extent of revascularization following primary intervention is unknown. We conducted a systematic review and meta-analysis of residual Syntax score (rSS) to predict the outcomes and provide guide to optimal management of revascularization following primary intervention. . Previously published studies from 2007 to 2020 assessing the prognostic impact of rSS after ACS were included for this meta-analysis. The primary endpoint was defined as the major adverse clinical events (MACE) in multivariable analysis. The risk ratios (RRs) with 95% confidence intervals (CI) were calculated using the RevMan 5.4 software. . A total of 8,157 participants complicated with ACS from 12 clinical studies were included in this analysis. Based on the wide range of rSS studies available, we classified it into two major groups: rSS < 8 and rSS ≥ 8. In multivariate analysis, the rSS was an independent risk marker for MACE [RR = 1.04 (95%CI; 1.00-1.08)], all-cause mortality [RR = 1.05 (1.03-1.07)] and cardiovascular death [RR = 1.05 (1.03-1.07)]. Patients with incomplete revascularization (ICR) showed higher prevalence of MACE along with all-cause mortality, cardiovascular morality, and recurrent myocardial infarction without significant heterogeneity [RR = 1.60 (1.03-1.07), 2.30 (1.57-3.38), 3.57 (2.09-6.10) and 1.70 (1.38-2.09), respectively]. The patients with rSS ≥ 8 presented higher frequency of all-cause mortality [RR = 2.99 (2.18-4.09)], cardiovascular death [RR = 3.32 (2.22-4.95)], and recurrent myocardial infarction [RR = 1.64 (1.34-2.02)]. . The meta-analysis indicated that an rSS value of 8 could be a reasonable cut-off for incomplete revascularization after ACS and is an efficient tool to guide revascularization. In future, detailed research should focus on investigation of the optimal value of the rSS score.

摘要

. 对于原发性介入治疗后再血管化的适当范围尚不清楚。我们进行了一项系统评价和荟萃分析,以剩余Syntax 评分(rSS)预测结果,并为原发性介入治疗后再血管化的最佳管理提供指导。. 本荟萃分析纳入了 2007 年至 2020 年期间评估 ACS 后 rSS 预后影响的已发表研究。主要终点是多变量分析中的主要不良临床事件(MACE)。使用 RevMan 5.4 软件计算风险比(RR)及其 95%置信区间(CI)。. 共有 12 项临床研究中的 8157 名 ACS 合并患者纳入本分析。根据 rSS 研究的广泛范围,我们将其分为两组:rSS<8 和 rSS≥8。多变量分析中,rSS 是 MACE [RR=1.04(95%CI;1.00-1.08)]、全因死亡率 [RR=1.05(1.03-1.07)] 和心血管死亡 [RR=1.05(1.03-1.07)]的独立危险因素。不完全血运重建(ICR)患者的 MACE 发生率更高,全因死亡率、心血管死亡率和复发性心肌梗死的发生率更高,但无明显异质性 [RR=1.60(1.03-1.07)、2.30(1.57-3.38)、3.57(2.09-6.10)和 1.70(1.38-2.09)]。rSS≥8 的患者全因死亡率 [RR=2.99(2.18-4.09)]、心血管死亡 [RR=3.32(2.22-4.95)]和复发性心肌梗死 [RR=1.64(1.34-2.02)]的频率更高。. 荟萃分析表明,rSS 值为 8 可能是 ACS 后不完全血运重建的合理截止值,是指导血运重建的有效工具。未来,应详细研究确定 rSS 评分的最佳值。

相似文献

1
Holistic review and meta-analysis of independent impact of the residual SYNTAX score on prognosis in patients with acute coronary syndrome.整体回顾与荟萃分析:SYNTAX 残余评分对急性冠脉综合征患者预后的独立影响。
Scand Cardiovasc J. 2022 Dec;56(1):187-197. doi: 10.1080/14017431.2022.2095434.
2
Beta-blockers in patients without heart failure after myocardial infarction.心肌梗死后无心力衰竭的患者使用β受体阻滞剂。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
3
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.生物标志物对改良心脏风险指数在预测非心脏手术患者主要不良心脏事件和全因死亡率方面的比较和附加预后价值。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD013139. doi: 10.1002/14651858.CD013139.pub2.
4
Exercise-based cardiac rehabilitation for coronary heart disease.基于运动的冠心病心脏康复。
Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.减少或无麸质饮食对心血管疾病一级预防的影响。
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
7
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.全身性皮质类固醇治疗 COVID-19:与公平相关的分析和证据更新。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2.
8
Smoking cessation for secondary prevention of cardiovascular disease.戒烟对心血管疾病二级预防的作用。
Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2.
9
Injection sclerotherapy for varicose veins.注射硬化疗法治疗静脉曲张。
Cochrane Database Syst Rev. 2021 Dec 10;12(12):CD001732. doi: 10.1002/14651858.CD001732.pub3.
10
Transfusion thresholds for guiding red blood cell transfusion.输血阈值指导红细胞输血。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.

引用本文的文献

1
Safety and Efficacy of Orbital Atherectomy in the All-Comer Population: Mid-Term Results of the Lower Silesian Orbital Atherectomy Registry (LOAR).全人群中眼眶斑块旋切术的安全性和有效性:下西里西亚眼眶斑块旋切术登记处(LOAR)的中期结果
J Clin Med. 2023 Sep 8;12(18):5842. doi: 10.3390/jcm12185842.